Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, awETN40

Urakami, A and Todo, S and Zhu, Y and Zhang, S and Jin, MB and Ishizaki, N and Shimamura, T and Totsuka, E and Subbotin, V and Lee, R and Starzl, TE (1997) Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, awETN40. Journal of the American College of Surgeons, 185 (4). 358 - 364. ISSN 1072-7515

Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Enhanced production of endothelin-1 (ET1), vasoconstrictive 21 amino acids produced by endothelial cells during ischemia and after reperfusion of the liver, is known to cause sinusoidal constriction and microcirculatory disturbances, which lead to severe tissue damage. Using a 2- hour hepatic vascular exclusion model in dogs, we tested our hypothesis that neutralization of ET-1 by monoclonal anti-ET-1 and anti-ET-2 antibody (AwETN40) abates vascular dysfunction and ameliorates ischemia/reperfusion injury of the liver. Study Design: After skeletonization, the liver was made totally ischemic by cross-clamping the portal vein, the hepatic artery, and the vena cava (above and below the liver). Venovenous bypass was used to decompress splanchnic and inferior systemic congestion. AwETN40, 5 mg/kg, was administered intravenously 10 minutes before ischemia (treatment group, n = 5). Nontreated animals were used as controls (control group, n = 10). Animal survival, hepatic tissue blood flow, liver function tests; total bile acid, high-energy phosphate, ET-1 levels, and liver histopathology were studied. Results: Treatment with AwETN40 improved 2-week animal survival from 30% to 100%. Hepatic tissue blood flow after reperfusion was significantly higher in the treatment group. The treatment significantly attenuated liver enzyme release, total bile acid, and changes in adenine nucleotides. Immunoreactive ET-1 levels in the hepatic venous blood of the control group showed a significant increase and remained high for up to 24 hours after reperfusion. Histopathologic alterations were significantly lessened in the treatment group. Conclusions: These results indicate that ET-1 is involved in ischemia/reperfusion injury of the liver, which can be ameliorated by the monoclonal anti-ET-1 and antiET-2 antibody AwETN40.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Urakami, A
Todo, S
Zhu, Y
Zhang, S
Jin, MB
Ishizaki, N
Shimamura, T
Totsuka, E
Subbotin, V
Lee, R
Starzl, TEtes11@pitt.eduTES11
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1997
Date Type: Publication
Journal or Publication Title: Journal of the American College of Surgeons
Volume: 185
Number: 4
Page Range: 358 - 364
DOI or Unique Handle: 10.1016/s1072-7515(97)00025-2
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 1072-7515
Other ID: uls-drl:31735062127273, Starzl CV No. 2006
Date Deposited: 08 Apr 2010 17:34
Last Modified: 04 Feb 2019 22:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item